AstraZeneca to Buy U.S. Cardiorenal-Drug Maker

[ad_1]


For an initial $1.3 billion, the Anglo-Swedish company will acquire CinCor Pharma, including rights to its baxdrostat cardiorenal drug, which has shown promise in clinical trials.

[ad_2]

Source link